Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

ABCG2 is not able to catalyze glutathione efflux and does not contribute to GSH-dependent collateral sensitivity.

Gauthier C, Ozvegy-Laczka C, Szakacs G, Sarkadi B, Di Pietro A.

Front Pharmacol. 2013 Nov 7;4:138. doi: 10.3389/fphar.2013.00138.

2.
3.

Dinaciclib, a cyclin-dependent kinase inhibitor, is a substrate of human ABCB1 and ABCG2 and an inhibitor of human ABCC1 in vitro.

Cihalova D, Ceckova M, Kucera R, Klimes J, Staud F.

Biochem Pharmacol. 2015 Dec 1;98(3):465-72. doi: 10.1016/j.bcp.2015.08.099.

PMID:
26300056
4.

Collateral sensitivity of resistant MRP1-overexpressing cells to flavonoids and derivatives through GSH efflux.

Lorendeau D, Dury L, Genoux-Bastide E, Lecerf-Schmidt F, Simões-Pires C, Carrupt PA, Terreux R, Magnard S, Di Pietro A, Boumendjel A, Baubichon-Cortay H.

Biochem Pharmacol. 2014 Aug 1;90(3):235-45. doi: 10.1016/j.bcp.2014.05.017.

PMID:
24875445
5.

Jadomycins are cytotoxic to ABCB1-, ABCC1-, and ABCG2-overexpressing MCF7 breast cancer cells.

Issa ME, Hall SR, Dupuis SN, Graham CL, Jakeman DL, Goralski KB.

Anticancer Drugs. 2014 Mar;25(3):255-69. doi: 10.1097/CAD.0000000000000043.

PMID:
24231527
7.

A combination of curcumin with either gramicidin or ouabain selectively kills cells that express the multidrug resistance-linked ABCG2 transporter.

Rao DK, Liu H, Ambudkar SV, Mayer M.

J Biol Chem. 2014 Nov 7;289(45):31397-410. doi: 10.1074/jbc.M114.576819.

8.

Glutathione transport is a unique function of the ATP-binding cassette protein ABCG2.

Brechbuhl HM, Gould N, Kachadourian R, Riekhof WR, Voelker DR, Day BJ.

J Biol Chem. 2010 May 28;285(22):16582-7. doi: 10.1074/jbc.M109.090506.

9.

Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivo.

Sodani K, Patel A, Anreddy N, Singh S, Yang DH, Kathawala RJ, Kumar P, Talele TT, Chen ZS.

Biochem Pharmacol. 2014 May 1;89(1):52-61. doi: 10.1016/j.bcp.2014.02.012.

10.

Linsitinib (OSI-906) antagonizes ATP-binding cassette subfamily G member 2 and subfamily C member 10-mediated drug resistance.

Zhang H, Kathawala RJ, Wang YJ, Zhang YK, Patel A, Shukla S, Robey RW, Talele TT, Ashby CR Jr, Ambudkar SV, Bates SE, Fu LW, Chen ZS.

Int J Biochem Cell Biol. 2014 Jun;51:111-9. doi: 10.1016/j.biocel.2014.03.026.

PMID:
24726739
11.

Dual properties of hispidulin: antiproliferative effects on HepG2 cancer cells and selective inhibition of ABCG2 transport activity.

Scoparo CT, Valdameri G, Worfel PR, Guterres FA, Martinez GR, Winnischofer SM, Di Pietro A, Rocha ME.

Mol Cell Biochem. 2015 Nov;409(1-2):123-33. doi: 10.1007/s11010-015-2518-8.

PMID:
26209062
12.

Sulindac sulfide selectively increases sensitivity of ABCC1 expressing tumor cells to doxorubicin and glutathione depletion.

Whitt JD, Keeton AB, Gary BD, Sklar LA, Sodani K, Chen ZS, Piazza GA.

J Biomed Res. 2016 Mar;30(2):120-133. doi: 10.7555/JBR.30.20150108.

14.

ABCG2/BCRP: Specific and Nonspecific Modulators.

Peña-Solórzano D, Stark SA, König B, Sierra CA, Ochoa-Puentes C.

Med Res Rev. 2016 Dec 22. doi: 10.1002/med.21428. [Epub ahead of print] Review.

PMID:
28005280
15.

Hop-derived prenylflavonoids are substrates and inhibitors of the efflux transporter breast cancer resistance protein (BCRP/ABCG2).

Tan KW, Cooney J, Jensen D, Li Y, Paxton JW, Birch NP, Scheepens A.

Mol Nutr Food Res. 2014 Nov;58(11):2099-110. doi: 10.1002/mnfr.201400288.

PMID:
25044854
16.

Karanjin interferes with ABCB1, ABCC1, and ABCG2.

Michaelis M, Rothweiler F, Nerreter T, Sharifi M, Ghafourian T, Cinatl J.

J Pharm Pharm Sci. 2014;17(1):92-105.

17.

Resistance to mitoxantrone in multidrug-resistant MCF7 breast cancer cells: evaluation of mitoxantrone transport and the role of multidrug resistance protein family proteins.

Diah SK, Smitherman PK, Aldridge J, Volk EL, Schneider E, Townsend AJ, Morrow CS.

Cancer Res. 2001 Jul 15;61(14):5461-7.

18.

Collateral sensitivity: ABCG2-overexpressing cells are more vulnerable to oxidative stress.

Krzyżanowski D, Bartosz G, Grzelak A.

Free Radic Biol Med. 2014 Nov;76:47-52. doi: 10.1016/j.freeradbiomed.2014.07.020.

19.

PD173074, a selective FGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells.

Patel A, Tiwari AK, Chufan EE, Sodani K, Anreddy N, Singh S, Ambudkar SV, Stephani R, Chen ZS.

Cancer Chemother Pharmacol. 2013 Jul;72(1):189-99. doi: 10.1007/s00280-013-2184-z.

PMID:
23673445
20.

Human ABCB1 (P-glycoprotein) and ABCG2 mediate resistance to BI 2536, a potent and selective inhibitor of Polo-like kinase 1.

Wu CP, Hsiao SH, Sim HM, Luo SY, Tuo WC, Cheng HW, Li YQ, Huang YH, Ambudkar SV.

Biochem Pharmacol. 2013 Oct 1;86(7):904-13. doi: 10.1016/j.bcp.2013.08.004.

Supplemental Content

Support Center